Celyad Announces February and March 2020 Conference Schedule

Celyad Announces February and March 2020 Conference Schedule

Letter to Shareholders - January 2020

Letter to Shareholders - January 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Announces Board of Directors Evolution with New Appointment

Celyad Announces Board of Directors Evolution with New Appointment

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad Announces October and November 2019 Investor Conference Schedule